5 completed, 3 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Terminated 3 |
| Phase 2 | 1 | Completed 1 |
Follow Pure Autonomic Failure: new trials by email Literature Review of Pure Autonomic Failure trials Research Report on Pure Autonomic Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Terminated | Theravance Biopharma | 110 | 2019-09-19 | 2022-11-30 |
| Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, MSA | Phase 3 | Terminated | Theravance Biopharma | 203 | 2019-02-22 | 2023-01-20 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Droxidopa, Placebo - Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease | Phase 3 | Terminated | Chelsea Therapeutics | 61 | 2013-11-01 | 2016-01-08 |
| Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg - Autoimmune Autonomic Ganglionopathy (AAG) | Phase 2 / Phase 3 | Completed | Beth Israel Deaconess Medical Center | 6 | 2012-02-01 | 2017-07-02 |
| A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 263 | 2008-09-01 | 2014-05-16 |
| Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Droxidopa, Placebo - Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 103 | 2008-01-01 | 2014-05-16 |
| Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 181 | 2008-01-01 | 2014-05-20 |
Hypotension, Orthostatic (6) · Multiple System Atrophy (4) · Parkinson Disease (4) · dopamine beta hydroxylase deficiency (4) · Dizziness (3) · Hypotension (3) · Syncope (3) · Parkinsonian Disorders (2) · Autonomic Nervous System Diseases (1)
Nervous System Diseases (8) · Primary Dysautonomias (8) · Autonomic Nervous System Diseases (7) · Basal Ganglia Diseases (7) · Brain Diseases (7) · Cardiovascular Diseases (7) · Central Nervous System Diseases (7) · Movement Disorders (7) · Neurodegenerative Diseases (7) · Synucleinopathies (7) · Vascular Diseases (7) · Orthostatic Intolerance (6) · Hypotension (4) · Consciousness Disorders (3) · Neurobehavioral Manifestations (3)
Droxidopa (4) · ampreloxetine (3) · Immunoglobulins, Intravenous (1) · Mannitol (1)
Chelsea Therapeutics (4) · Theravance Biopharma (3) · Beth Israel Deaconess Medical Center (1)
United States (8) · Canada (6) · Australia (5) · New Zealand (5) · Austria (3) · Bulgaria (3) · Denmark (3) · Estonia (3) · France (3) · Germany (3) · Israel (3) · Italy (3) · Poland (3) · Portugal (3) · Russia (3)
Roy Freeman, MD (2) · Alberto Vasquez, MD (1) · Alvin McElveen, MD (1) · Brent Goodman, MD (1) · Christopher J Mathias, MD (1) · Christopher J. Mathias, MD (1) · Horacio Kaufmann Kaufmann, MD (1) · Horacio Kaufmann, M.D. (1) · Horacio Kaufmann, MD (1) · Mazen Dimachkie, MD (1) · Phillip A Low, MD (1) · Richard Hull, MD (1) · Stephen Greer, MD (1)
PMID 27538531, PMID 28494751, PMID 42475649, PMID 25350981
2018 (2), 2019 (1), U54NS065736 (1)